Nymox Announces New Pooled Analysis Confirms 12 Month Benefit of NX-1207 Treatment...

Nymox Announces New Pooled Analysis Confirms 12 Month Benefit of NX-1207
Treatment for BPH

HASBROUCK HEIGHTS, N.J., Oct. 5, 2009 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical
Corporation (Nasdaq:NYMX) is pleased to announce that a new formal statistical
analysis of double-blind clinical trial data from pooled subjects in Phase 2
clinical trials for NX-1207, the Company's investigational treatment for BPH,
confirmed that clinically significant benefits of a single NX-1207 treatment
extend to 12 months or longer.

The new analysis pooled the results from double-blind follow-up studies
involving 159 men treated with a single injection of either placebo or NX-1207.
A statistically significant difference in standardized BPH symptom score
improvement at mean 13.5 months after a single treatment was found between
NX-1207 2.5 mg (the therapeutic dose of NX-1207) and placebo. The median
improvement in BPH Symptom Score in subjects given a single injection of NX-1207
at 12 months was 9.0 points (p less than .003).

NX-1207 is currently being tested in Phase 3 clinical trials in centers across
the U.S.

This new data provides solid evidence accompanying and confirming earlier
reports of a significant proportion of patients who received a single dose of
NX-1207 and maintained their improvement in BPH symptoms for up to 5 years.

Urologists in the U.S. have expressed very positive comments about the potential
of NX-1207 to improve the care of millions of men with BPH.

Completed clinical trials to date have shown that men treated with NX-1207
reported statistically significant improvement in BPH symptoms 3 months after a
single NX-1207 treatment with no reported serious drug-related side effects,
including no (0%) significant sexual side effects. In two multi-center Phase 2
U.S. prospective randomized blinded clinical trials, the aggregated mean
improvement in the BPH symptom score for 2.5 mg NX-1207 was 10.3 points or a 44%
improvement in BPH symptom score. By comparison, currently approved drugs for
BPH provide on average 3 to 5 points improvement, must be taken daily to achieve
or maintain benefit, and often have unwanted side effects such as impotence,
loss of libido, retrograde ejaculation, dizziness, and weakness.

NX-1207 involves a new targeted approach to the treatment of BPH. NX-1207 is
injected by a urologist in an office setting directly into the zone of the
prostate where the enlargement occurs. The entire procedure lasts on average
5-10 minutes, with the injection taking 1-2 minutes, does not require anesthesia
or catheterization, and involves little or no pain or discomfort.

BPH treatment represents a growing market with more than 100 million men
worldwide being estimated to suffer from BPH symptoms. The disorder is a common
affliction of older men, affecting approximately half of men over age 50 and
close to 90% of men by age 80, and is associated with growth in prostate size as
men age. BPH causes difficulties with urination associated with aging, such as
urination at night, urge to void frequently, hesitancy, weak stream, and other
problems.

More information about Nymox is available at www.nymox.com, email:
info@nymox.com, or 800-936-9669.

This press release contains certain "forward-looking statements" as defined in
the United States Private Securities Litigation Reform Act of 1995 that involve
a number of risks and uncertainties. There can be no assurance that such
statements will prove to be accurate and the actual results and future events
could differ materially from management's current expectations. Development of
drug products involves substantial risks and actual results may differ
materially from expectations. Such factors are detailed from time to time in
Nymox's filings with the United States Securities and Exchange Commission and
other regulatory authorities.

-0-
CONTACT: Nymox Pharmaceutical Corporation
Roy Wolvin
1-800-93NYMOX
www.nymox.com